Microalbuminuria in Patients with Type 2 Diabetes Mellitus Treated with a Phytoformula as Adjuvant.

IF 3.5 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American heart journal Pub Date : 2024-12-01 Epub Date: 2024-12-02 DOI:10.1016/j.ahj.2024.09.019
Nidia Angélica García Espinoza DACM , Hugo Morales Tello DACM , Ricardo Sacchi Córdova BS , Nicasio Morales Sarabia BS , Jair Isaí Ortega Gaxiola PhD , José Alfredo Primelles Gingele BS , María Magdalena Valencia Gutiérrez MD, MPH , Erick Ayala Calvillo PhD , Cesar Ochoa Martinez MD, PhD
{"title":"Microalbuminuria in Patients with Type 2 Diabetes Mellitus Treated with a Phytoformula as Adjuvant.","authors":"Nidia Angélica García Espinoza DACM ,&nbsp;Hugo Morales Tello DACM ,&nbsp;Ricardo Sacchi Córdova BS ,&nbsp;Nicasio Morales Sarabia BS ,&nbsp;Jair Isaí Ortega Gaxiola PhD ,&nbsp;José Alfredo Primelles Gingele BS ,&nbsp;María Magdalena Valencia Gutiérrez MD, MPH ,&nbsp;Erick Ayala Calvillo PhD ,&nbsp;Cesar Ochoa Martinez MD, PhD","doi":"10.1016/j.ahj.2024.09.019","DOIUrl":null,"url":null,"abstract":"<div><div><strong>Introduction:</strong> Diabetic nephropathy develops in 40% of patients 10 years after the diagnosis of diabetes, with albuminuria &gt;300mg/dl (&gt;200µg/min) more than twice in 3-6 months. (1) Strict glycemic control reduces mortality by 48% (2) and macroalbuminuria by 50%. The Terrabrio SAPI de CV group developed the Elevaté® Body Balance phytoformula made with Shilajit (Asphaltum punjabianum), Chaga (Inonotus obliquus), Moringa (Moringa oleifera), Berberine (Berberina vulgaris, Coptis chinensis French) and Bayetilla (Hamelia patens) used in traditional herbal medicine.</div><div><strong>Objective:</strong> To evaluate changes in albuminuria in patients with DM2 treated with a phytoformula as adjuvant therapy.</div><div><strong>Methods:</strong> A controlled clinical trial was conducted in 269 patients with DM2 treated with oral hypoglycemic agents plus 1.5 g/day of the phytoformulation under treatment for 90 days; a sub analysis of 20 patients with albuminuria was performed.</div><div><strong>Results:</strong> In the 20 patients with albuminuria, age was 53.20 (49.25-58) years, 12(60%) women and 8(40%) men; time of diagnosis of DM2 was 7.41±4.36 years, treated with metformin 16(80%), sulfonylureas 19(95%) and insulin 3(15%); 3-month changes in waist from 95.85±9. 82 to 93.80±10.34 with p 0.044; HbA1c from 9.82±1.24 to 7.28±1.70 with p 0.0001; BUN from 10.44±3.43 to 12.30±5.53 with p 0.023; Albuminuria from 43.50±36.45 to 30±35.39 with p 0.0001; GFR from 93.57±14.54 to 93.85±18.56 with p 0.908, with no differences in BMI, blood pressure, urea, and creatinine. Correlation was 0.795 between HbAc1 and albuminuria.</div><div><strong>Conclusions:</strong> Phytoformula reduced waist, HbA1c and albuminuria at 3 months; no changes in BMI and GFR were present.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Pages 6-7"},"PeriodicalIF":3.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324002527","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Diabetic nephropathy develops in 40% of patients 10 years after the diagnosis of diabetes, with albuminuria >300mg/dl (>200µg/min) more than twice in 3-6 months. (1) Strict glycemic control reduces mortality by 48% (2) and macroalbuminuria by 50%. The Terrabrio SAPI de CV group developed the Elevaté® Body Balance phytoformula made with Shilajit (Asphaltum punjabianum), Chaga (Inonotus obliquus), Moringa (Moringa oleifera), Berberine (Berberina vulgaris, Coptis chinensis French) and Bayetilla (Hamelia patens) used in traditional herbal medicine.
Objective: To evaluate changes in albuminuria in patients with DM2 treated with a phytoformula as adjuvant therapy.
Methods: A controlled clinical trial was conducted in 269 patients with DM2 treated with oral hypoglycemic agents plus 1.5 g/day of the phytoformulation under treatment for 90 days; a sub analysis of 20 patients with albuminuria was performed.
Results: In the 20 patients with albuminuria, age was 53.20 (49.25-58) years, 12(60%) women and 8(40%) men; time of diagnosis of DM2 was 7.41±4.36 years, treated with metformin 16(80%), sulfonylureas 19(95%) and insulin 3(15%); 3-month changes in waist from 95.85±9. 82 to 93.80±10.34 with p 0.044; HbA1c from 9.82±1.24 to 7.28±1.70 with p 0.0001; BUN from 10.44±3.43 to 12.30±5.53 with p 0.023; Albuminuria from 43.50±36.45 to 30±35.39 with p 0.0001; GFR from 93.57±14.54 to 93.85±18.56 with p 0.908, with no differences in BMI, blood pressure, urea, and creatinine. Correlation was 0.795 between HbAc1 and albuminuria.
Conclusions: Phytoformula reduced waist, HbA1c and albuminuria at 3 months; no changes in BMI and GFR were present.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
植物方辅助治疗2型糖尿病患者的微量白蛋白尿。
导读:40%的患者在糖尿病诊断后10年发生糖尿病肾病,在3-6个月内出现两次以上的蛋白尿>;300mg/dl (> 200ug /min)。(1)严格控制血糖可降低48%的死亡率(2)和50%的大量蛋白尿。Terrabrio SAPI de CV集团开发了elevat®Body Balance植物配方,由旁jabianum沥青、Chaga (Inonotus obliquus)、辣木(Moringa oleifera)、小檗(Berberina vulgaris, Coptis chinensis French)和巴伐利亚(Hamelia patens)等传统草药制成。目的:评价植物方剂辅助治疗DM2患者蛋白尿的变化。方法:对269例口服降糖药加1.5 g/d植物制剂治疗的DM2患者进行对照临床试验,治疗90 d;对20例蛋白尿患者进行亚组分析。结果:20例蛋白尿患者中,年龄53.20(49.25 ~ 58)岁,女性12例(60%),男性8例(40%);诊断DM2的时间为7.41±4.36年,其中二甲双胍16例(80%),磺脲类19例(95%),胰岛素3例(15%);3个月腰围变化从95.85±9。82 ~ 93.80±10.34,p < 0.044;HbA1c从9.82±1.24降至7.28±1.70,p为0.0001;BUN由10.44±3.43降至12.30±5.53,p值为0.023;蛋白尿从43.50±36.45降至30±35.39,p为0.0001;GFR从93.57±14.54降至93.85±18.56,p为0.908,BMI、血压、尿素和肌酐无差异。HbAc1与蛋白尿的相关性为0.795。结论:植物方在3个月时降低腰围、糖化血红蛋白和蛋白尿;BMI和GFR均无变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American heart journal
American heart journal 医学-心血管系统
CiteScore
8.20
自引率
2.10%
发文量
214
审稿时长
38 days
期刊介绍: The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.
期刊最新文献
Design and rationale of a multicenter paramedic randomized trial of noradrenaline versus adrenaline in the initial management of patients with cardiogenic shock—The PANDA trial Integration of a task strengthening strategy for hypertension management into HIV care in Nigeria: Baseline characteristics of participants in a cluster randomized controlled trial Design and rationale of the COMPARE-TAVI 2 trial: An all-comers head-to-head comparison of Evolut FX+ and Sapien 3 Ultra Resilia transcatheter heart valves Remote dietitian counseling with short-term meal delivery improves DASH diet adherence and lowers blood pressure in veterans with hypertension and obesity Operator radiation exposure comparing left-radial artery and right-radial artery approaches: A systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1